Introduction {#Sec1}
============

Cardiogenic shock following myocardial infarction has a poor prognosis with mortality between 40 and 60% \[[@CR6]\]. Prognosis improves with PCI. However, in many cases despite maximum therapy including inotropic agents and IABP cardiac output and blood pressure are not adequate to prevent progressive organ failure. Therefore, new strategies to rapidly improve hemodynamics after PCI are urgently needed.

It has been suggested recently that pyruvate which is a key intermediate in the glycolytic and pyruvate dehydrogenase pathways shows beneficial hemodynamic effects. The use of different animal species showed that pyruvate exerted positive inotropic effects in vitro \[[@CR19]\] and in vivo \[[@CR12], [@CR13], [@CR15], [@CR23]\]. Similar results were found in isolated multicellular preparations from end-stage failing human hearts \[[@CR7]\]. Measuring oxygen consumption by the diffusion-microelectrode technique in isolated contracting rabbit myocardium, it could be demonstrated that economy of myocardial contraction remained unchanged with pyruvate despite a substantial increase in force--time integral whereas β-adrenergic stimulation decreased economy \[[@CR11]\]. Moreover, pyruvate potentiated the inotropic response of β-adrenergic stimulation in isolated animal \[[@CR21]\] and human myocardium \[[@CR10]\]. Previous in vivo studies in patients with chronic compensated heart failure have demonstrated increased CO, improved relaxation and decreased left ventricular filling pressure and HR with intracoronary pyruvate infusion \[[@CR8], [@CR9]\].

Thus, pyruvate may have beneficial effects in acute severe heart failure and cardiogenic shock, but no data is currently available directly supporting this hypothesis. We therefore investigated the effects of intracoronary pyruvate infusion in patients with severe circulatory failure due to acute coronary syndrome necessitating pharmacological and mechanical support.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Patients were eligible for participation if they were presenting with cardiogenic shock because of acute myocardial infarction and if primary PCI could be successfully performed. Cardiogenic shock was defined according to current guidelines \[[@CR2]\]. Detailed inclusion and exclusion criteria are given in Table [1](#Tab1){ref-type="table"}. Written informed consent was obtained from patients or close relatives in unconscious patients prior to the study. Alternatively, the study was performed with regard to the patients' presumed will. In the latter ones, written consent was obtained as soon as possible after study termination from patients after having regained consciousness or from close relatives. One patient with presumed anterior wall STEMI at the initial evaluation was excluded from further analyses because continuative evaluation revealed chronic anterior wall aneurysm by echocardiography, absence of rise in troponin t, failure of ST segment resolution after successful PCI, and significant decompensated aortic stenosis as the cause of acute cardiac failure. Eight patients were included in the final analyses: one was female and seven were male. The median age was 68 years (range 40--84). All patients were on treatment with catecholamines (epinephrine 0.03--0.34 μg kg min^−1^, *n* = 6; norepinephrine 0.03--0.63 μg kg min^−1^, *n* = 5). HR was 89 ± 18 min^−1^ and systolic pressure was 92 ± 8 mmHg (mean ± 95% CI). The study was reviewed and approved by the ethical committee of the University Medical Center of Goettingen.Table 1Inclusion and exclusion criteriaInclusion criteriaExclusion criteriaAge, 18--85 yearsFailure of PCI or need for CABGWeight, 45--110 kgCardiogenic shock of other origin than ischemic (e.g., tamponade, valvular disease, arrhythmogenic)Height, 150--195 cmInstability necessitating significant change of conditions (e.g., catecholamine dose, ventilation) before pyruvate infusionAcute myocardial infarctionFailure to insert intra-aortic balloon pumpSuccessful primary PCIMalignant tumorCardiogenic shockPregnancy or lactationNeed for catecholamines or intra-aortic balloon pumpPoor complianceStable conditions in hemodynamics, rhythm and ventilation before pyruvate infusionAlcohol or drug abuseParticipation in concurrent clinical trial

Cardiac catheterization and treatment of myocardial infarction {#Sec4}
--------------------------------------------------------------

Cardiac catheterization, PCI and placement of an IABP were performed according to current guidelines \[[@CR1], [@CR2], [@CR22]\]. After termination of PCI the guiding catheter was left in the ostium of the coronary artery. During these interventions all measures were undertaken to obtain stable conditions prior to the study protocol: Catecholamine doses and ventilation conditions were adjusted to obtain sufficient hemodynamics and blood gases. Sedatives and muscle relaxants were administered as needed. Bicarbonate was administered to counterbalance acidosis if present. Comatose survivors of cardiac arrest were cooled to 32°--34°C by infusion of cold NaCl 0.9% solution for reasons of neuroprotection. 150--300 mg of amiodarone was injected if relevant arrhythmias were present. After these measures, all conditions were kept stable.

Measurements of intracoronary pyruvate effects {#Sec5}
----------------------------------------------

A 7F Swan--Ganz catheter was placed in the pulmonary artery from a femoral vein. About 30--45 min after having performed all interventions and having gained stable conditions; CI was determined in triplicate by the thermodilution technique and PCWP was measured. After a waiting period of 30 min in order to assure stable conditions, intracoronary NaCl 0.9% was administered via the guiding catheter with an infusion rate of 360 mL/h. After 10 min, HR, SAP, RAP, PAP, PCWP, SVI and CI were determined. After these measurements, intracoronary NaCl 0.9% infusion was stopped and intracoronary pyruvate 300 mmol/L was administered at an identical infusion rate of 360 mL/h for 30 min. Every 10 min, hemodynamic measurements were repeated. Then, pyruvate was stopped and intracoronary NaCl 0.9% (360 mL/h) was given for another 10 min followed by final hemodynamic measurements. After termination of measurements, patients were transferred to the intensive care unit, immediately, and subjected to standard treatment.

Statistical analyses {#Sec6}
--------------------

GraphPad Prizm Version 5 was used for statistical analyses. Previous studies in stable patients with chronic heart failure showed statistically significant effects of intracoronary pyruvate in small numbers of patients (8, 9). Because of the expected difficulties in patient recruitment, the study protocol allowed analyses of data after eight patients and termination of the study if statistically significant differences were present. Data are expressed as mean ± 95% confidence interval. Differences between means were tested for statistical significance by 1-way repeated measures ANOVA followed by Newman--Keuls multiple comparison tests. A *p* value of \<0.05 was accepted as statistically significant.

Results {#Sec7}
=======

A summary of hemodynamic measurements and pyruvate effects is given in Table [2](#Tab2){ref-type="table"}. Cardiac performance was severely impaired in all patients. Baseline hemodynamics directly before pyruvate were as follows: CI 2.07 ± 0.47, HR 76 ± 8, SVI 27 ± 5, mean SAP 93 ± 7, mean PCWP 23 ± 6. Continuous intracoronary pyruvate infusion induced an increase in CI that amounted to 2.23 ± 0.53 L min^−1^ m^−2^ after 30 min. After intracoronary pyruvate was stopped, CI rapidly dropped down to 1.95 ± 0.45 L min^−1^ m^−2^ within 10 min (*p* \< 0.05, Fig. [1](#Fig1){ref-type="fig"}). Similarly, there was a rise in SVI to 29 ± 6 mL m^−2^ after 30 min pyruvate. After pyruvate was stopped SVI declined to 26 ± 5 mL m^−2^ within 10 min (*p* \< 0.05, Fig. [1](#Fig1){ref-type="fig"}). Mean SAP was 95 ± 9 mmHg after 30 min of intracoronary pyruvate infusion and decreased to 87 ± 9 mmHg 10 min after pyruvate was stopped (Fig. [1](#Fig1){ref-type="fig"}). Even though these effects were not pronounced, an increase in CI, SVI, and mean SAP was clearly found in most patients and differences as a result of the intervention were statistically significant (Fig. [1](#Fig1){ref-type="fig"}). By comparing hemodynamics after 30 min of pyruvate infusion (point in time 40 min) to values 10 min after cessation (point in time 50 min), we calculated a net positive pyruvate effect of 15 ± 5% on CI, of 16 ± 5% on SVI, and of 10 ± 8% on mean SAP in addition to catecholamine treatment and mechanical support by IABP. CI, SVI, and mean SAP tended to drop after termination of pyruvate infusion as compared to baseline values; however, neither of these changes was statistically significant. In parallel to changes in CI, SVI, and mean SAP, there was a tendency for a drop in SVR and PVR under the influence of pyruvate. Yet, these changes were not statistically significant as well. Pyruvate did not induce significant changes in HR, mean PCWP, mean RAP, and mean PAP (Table [2](#Tab2){ref-type="table"}).Table 2Hemodynamic effects of intracoronary pyruvate in addition to catecholamines and IABPIntervention (point in time)Pyruvate (40 min)NaCl 0.9% (50 min)HR (min^−1^)76 ± 976 ± 7CI (L min^−1^ m^−2^)2.23 ± 0.531.95 ± 0.45\*SVI (mL m^−2^)29 ± 626 ± 5\*Mean SAP (mmHg)95 ± 987 ± 9Mean PAP (mmHg)33 ± 631 ± 4Mean PCWP (mmHg)23 ± 722 ± 4Mean RAP (mmHg)16 ± 316 ± 3SVR (dyn s cm^−5^)1,608 ± 3541,635 ± 325PVR (dyn s cm^−5^)216 ± 136236 ± 159\* Means *p* \< 0.05Fig. 1Graphs showing changes in CI (**a**), SVI (**b**), and mean SAP (**c**) under the influence of NaCl 0.9% and pyruvate 300 mmol/L at different points in time. Interventions are indicated by *arrows*. There was a significant effect of pyruvate on each hemodynamic parameter as calculated by repeated measures ANOVA. \*Means *p* \< 0.05 versus 50 min. Neither of all parameters showed significant differences at 50 min as compared to 10 min indicating stable hemodynamics at baseline

Discussion {#Sec8}
==========

The present study shows that intracoronary pyruvate has positive inotropic effects in patients with cardiogenic shock despite medical treatment with catecholamines and mechanical support by IABP. We found an increase in CI and SVI by 15 ± 5 and 16 ± 5%, respectively, as an effect of pyruvate that was not secondary to increases in HR. Moreover, mean SAP was increased by 10 ± 8%. All other conditions were kept stable during pyruvate infusion and no significant differences of any hemodynamic parameter were detected between values at baseline and after complete reversal of pyruvate effects. Thus, these effects cannot be attributed to standard interventions related to treatment of myocardial infarction and cardiogenic shock or to changes in hemodynamics other than that caused by intracoronary pyruvate.

In a previous study, we could show that the observed beneficial effects of pyruvate on hemodynamics mainly resulted from direct myocardial effects and not from altered loading conditions because intracoronary pyruvate was almost completely extracted from the coronary circulation by the myocardium and did not induce systemic vasodilatation \[[@CR9]\]. Furthermore, it was shown that pyruvate does not induce coronary vasodilatation \[[@CR4]\]. The underlying mechanisms of pyruvate on the myocardium have been extensively investigated in animal and human myocardium \[[@CR4], [@CR7], [@CR10], [@CR12]--[@CR15], [@CR19], [@CR21], [@CR23]\]. It was demonstrated that pyruvate increases the energetic stimulation of the sarcoplasmic reticulum calcium pump due to an increase in phosphorylation potential with enhanced free energy of ATP hydrolysis \[[@CR4], [@CR19]\]. This promotes relaxation of the myofilaments and also results in enhanced calcium content of the sarcoplasmic reticulum, which in turn results in more calcium available for systolic release and activation of contractile proteins \[[@CR5], [@CR7]\]. In addition, it was shown that pyruvate increases intracellular pH which may partly result from uptake of pyruvate and protons into the mitochondria by the monocarboxylate--proton symporter \[[@CR7], [@CR17]\]. The increase in intracellular pH leads to an enhanced calcium sensitivity of contractile proteins and force development \[[@CR3]\].

These effects on the cellular and molecular level had been previously shown to translate into pronounced beneficial effects on systolic and diastolic cardiac performance in patients with chronic heart failure. In a previous study in patients with chronic stable heart failure, pyruvate increased cardiac index without increasing HR \[[@CR8], [@CR9]\]. These findings resulted from an increase in left ventricular ejection fraction \[[@CR8]\]. Moreover, positive effects on maximum rate of left ventricular isovolumic pressure rise were found by use of a micromanometer catheter \[[@CR8]\]. Interestingly, in the present study pyruvate exhibited beneficial effects on systolic cardiac performance in acute heart failure ancillary to IABP. IABP was suggested to increase left ventricular ejection fraction and CO \[[@CR16]\]. With regard to diastolic function, the previous studies in chronic heart failure demonstrated that pyruvate decreased PCWP \[[@CR9]\] and left ventricular end-diastolic pressure \[[@CR8]\]. Contrasting these findings, the effects of pyruvate on left ventricular filling pressure as measured by PCWP were absent in the present study. This lack of an unloading effect of pyruvate might be secondary to the action of IABP which induces a pronounced systolic unloading of the heart \[[@CR16]\] implying that potential effects of pyruvate on left ventricular preload might be masked by IABP. It is of note that the role of IABP in acute ischemic shock was recently questioned \[[@CR18], [@CR20]\]. The present study was designed and conducted in consideration of current guidelines that strongly recommend IABP in acute myocardial infarction complicated by shock \[[@CR1], [@CR22]\]. However, the evidence supporting this recommendation is rather limited. Thus, investigation of the effects of intracoronary pyruvate in acute heart failure without IABP might be mandatory.

After termination of pyruvate, CI, SVI, and mean SAP tended to drop below the baseline values. These changes were not statistically significant. However, examination of this phenomenon in further studies might be worthwhile in order to prevent a worse outcome due to sudden termination of therapy. The major shortcoming of pyruvate is the necessity of intracoronary application. Because it is rapidly metabolized and the hemodynamic effect requires doses above 1 mM very high doses would be necessary if it was administered intravenously. Such high doses, however, would lead to sodium overload and hyperosmolarity if the sodium salt of pyruvic acid was used as in the present study. However, in specialized centers with invasive facilities the intracoronary route might be an option for patients with cardiogenic shock refractory to standard care. Moreover, these problems may be overcome by the development of novel formulations such as the choline salt.

In summary, pyruvate might have the potential of a favorable agent in acute heart failure and might serve as an adjunctive therapy to catecholamines. It might save catecholamines that are potentially harmful. Moreover, the effects of pyruvate might especially help in acute ischemic heart failure because the inotropic effects of pyruvate occurred without worsening of myocardial economy. These potentially beneficial effects of pyruvate should be investigated in randomized controlled trials.
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